Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.

BACKGROUND Metastasectomy is routinely performed in selected patients with metastatic clear-cell renal cell carcinoma (ccRCC) as an alternative to systemic therapy. In the absence of randomized trials, the benefit and best way of patient selection remain unclear. Earlier, we described four molecular ccRCC-subtypes (ccrcc1-4) that have a prognostic and predictive value upon first-line sunitinib or pazopanib. OBJECTIVE Assess the prognostic value of ccrcc1-4 subtypes after complete metastasectomy. (1) Compare outcomes of good-prognosis ccrccc2&3-tumors with intermediate/poor-prognosis ccrcc1&4-tumors. (2) Compare outcomes of the four subtypes separately. DESIGN, SETTING, AND PARTICIPANTS Single-center retrospective study (1995-2017), assessing 43 ccRCC patients undergoing complete metastasectomy without systemic treatment. INTERVENTION Molecular subtype determined with established 35-gene expression classifier. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Median disease-free survival (DFS), time to systemic therapy, cancer-specific (CSS) and overall survival (OS) from metastasectomy, estimated with Kaplan-Meier method and tested against other predictors with multivariable Cox regression. RESULTS AND LIMITATIONS Median DFS was 23 mo for ccrcc2&3-tumors versus 9 mo for ccrcc1&4-tumors (p=0.011, hazard ratio [HR]=2.6). Median time to systemic therapy was 92 mo versus 28 mo (p=0.003, HR=3.3). Median CSS was 133 mo versus 50 mo (p<0.001, HR=2.7). Median OS was 127 mo versus 50 mo (p=0.011, HR=2.5). The classification remained independent upon multivariable analysis. Outcomes remained significantly different when comparing four subtypes separately. The intrinsic heterogeneity of expression profiles is a limitation of this approach. CONCLUSION Even after clinical patient selection, patients with a ccrcc1- or ccrcc4-tumor are at a higher risk of relapse after complete metastasectomy. Patients with a ccrcc2- or ccrcc3-tumor usually experience a long DFS. These results need validation in a larger cohort to establish the subtypes as prognostic marker. PATIENT SUMMARY Metastasectomy is recommended for some patients with metastatic clear-cell kidney cancer; however, we do not know who will benefit the most. We show that molecular subtypes increase the possibility to predict which patients are at risk for early relapse after metastasectomy and who may benefit more from other treatment options.

[1]  P. Russo,et al.  Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. , 2008, The Journal of urology.

[2]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[3]  B. Wang,et al.  The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy , 2015, BioMed research international.

[4]  R. Silber,et al.  Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. , 2005, European urology.

[5]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting , 2017, Clinical genitourinary cancer.

[7]  N. Rioux-Leclercq,et al.  Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma , 2017, Acta oncologica.

[8]  A. Borri,et al.  Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection? , 2008, Annals of Surgical Oncology.

[9]  U. Neumann,et al.  Liver Resection for Metastases from Renal Cell Carcinoma , 2007, World Journal of Surgery.

[10]  C. Kwak,et al.  Metastasectomy without Systemic Therapy in Metastatic Renal Cell Carcinoma: Comparison with Conservative Treatment , 2007, Urologia Internationalis.

[11]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[12]  H. Tsuchiya,et al.  Surgical metastasectomy for renal cell carcinoma: which patients are the real candidates for surgery? , 2019, Annals of translational medicine.

[13]  P. Hegde,et al.  Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients , 2017 .

[14]  Y. Tomita,et al.  Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. , 2013, Urology.

[15]  K. Bensalah,et al.  Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. , 2017, European urology.

[16]  M. Burt,et al.  Resection of metastatic renal cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Arun Z. Thomas,et al.  Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. , 2015, The Journal of urology.

[18]  S. Dabestani,et al.  Metastasis therapies for renal cancer , 2016, Current opinion in urology.

[19]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[20]  A. Crispin,et al.  Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. , 2011, American journal of surgery.

[21]  Gyan Bhanot,et al.  Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .

[22]  G. Di Lorenzo,et al.  Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer , 2019, Front. Oncol..

[23]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[24]  S. Joniau,et al.  Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. , 2013, European urology.

[25]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[26]  Gyan Bhanot,et al.  Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. , 2010, Genes & cancer.

[27]  E. Jonasch,et al.  Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma , 2009, BJU international.

[28]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[29]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[30]  S. Boorjian,et al.  Survival after complete surgical resection of multiple metastases from renal cell carcinoma , 2011, Cancer.

[31]  M. Staehler,et al.  Local treatments for metastases of renal cell carcinoma: a systematic review. , 2014, The Lancet. Oncology.

[32]  R. Motzer,et al.  Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer , 2007, TheScientificWorldJournal.

[33]  W. D. da Costa,et al.  Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model , 2019, Ecancermedicalscience.

[34]  Peng Guo,et al.  6-Gingerol induces cell-cycle G1-phase arrest through AKT–GSK 3β–cyclin D1 pathway in renal-cell carcinoma , 2019, Cancer Chemotherapy and Pharmacology.

[35]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[36]  Zoltan Szallasi,et al.  Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers , 2014, European urology.

[37]  E. Blackstone,et al.  Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? , 2005, The Annals of thoracic surgery.

[38]  B. Lambrecht,et al.  The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy , 2015, Oncoimmunology.